Systemic delivery of IL-10 by bone marrow derived stromal cells has therapeutic benefits in sepsis therapy

Progress in Biochemistry and Biophysics

Volumn 37, Issue 6, 2010, Pages 678-685

  Bi, Liang Kuan ^a   Tang, Bing ^a   Zhu, Bin ^a   Xie, Chun Ling ^a   Li, Shuang ^a   Lin, Tian Xin ^a   Huang, Jian ^a   Zhang, Wei ^a   Zhu, Jia Yuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bone marrow derived stromal cells (bmscs); Gene therapy; IL 10; Inflammation; Sepsis

Indexed keywords

ADENOVIRIDAE; MURINAE; MUS;

EID: 77954922603     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2010.00107     Document Type: Article

References (23)

1. Rung H C, Hoyert D L, Xu J, et al. Deaths: final data for 2005. Natl Vital Stat Rep, 2008, 56(8): 1-97
2. Russell J A. Management of sepsis. N Engl J Med, 2006, 355(10): 1699-1713
3. Rice T W, Bernard G R. Therapeutic intervention and targets for sepsis. Annu Rev Med, 2005, 56(1): 225-248
4. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 2004, 363(5): 1439-1441
5. Mansilla E, Marin G H, Sturla F, et al. Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries. Transplant Proc, 2005, 37(1): 292-294
6. van Laar J M, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology(Oxford), 2006, 45(10): 1187-1193
7. Minguell J J, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp Biol Med (Maywood), 2006, 231(1): 39-49
8. Ortiz L A, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA, 2003, 100(14): 8407-8411
9. Rojas M, Xu J, Woods C R, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152
10. Ortiz L A, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA, 2007, 104(26): 11002-11007
11. Runter U, Rong S, Djuric Z, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol, 2006, 17(8): 2202-2212
12. Lee R H, Seo M J, Reger R L, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA, 2006, 103(46): 17438-17443
13. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation, 2006, 81(10): 1390-1397
14. Phinney D G, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des, 2005, 11(10): 1255-1265
15. Florentino D F, Bond M W, Mosmann T R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med, 1989, 170(6): 2081-2095
16. Ogawa Y, Duru E A, Ameredes B T. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med, 2008, 8(5): 437-445
17. Etheridge S L, Spencer G J, Heath D J, et al. Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells, 2004, 22(5): 849-860
18. Hubbard W J, Choudhry M, Schwacha M G, et al. Cecal ligation and puncture. Shock, 2005, 24(Suppl 1): 52-57
19. Hayden M S, Ghosh S. Signaling to NF-kappaB. Genes, 2004, 18(18): 2195-2224
20. Huhn R D, Radwanski E, O'Connell S M, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood, 1996, 87(2): 699-705
21. Nemeth R, Leelahavanichkul A, Yuen P S, B. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E (2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 2009, 15(1): 42-49
22. Abraham E. Alterations in cell signaling in sepsis. Clin Infect Dis, 2005, 41(Suppl 7):S459-S464
23. Schmidt C, Rurt B, Hocherl R, et al. Inhibition of NF-kappaB activity prevents downregulation of alphal-adrenergic receptors and circulatory failure during CLP-induced sepsis. Shock, 2009, 32(3): 239-246